Last 12 months
Inside the activity.
0 purchase rows · 50 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 23 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 15 |
| Sep 2026 | 0 | 5 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 27, 2019 Filed Nov 29, 2019 19:40 UTC |
Foley ToddDirector
|
SaleCommon Stock | 34,960 | $22.91 | $800,933.60 |
DisclosureSEC source: 0001209191-19-058413 · doc4.xml · nonDerivative · entry 2 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,535,395 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · shares: Shares were sold as follows: 33,653 by BV V and 1,307 by AM BV5. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.41 to $23.385. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F7 · ownership.nature: Shares are held as follows: 2,440,583 by BV V and 94,812 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 26, 2019 Filed Nov 29, 2019 19:40 UTC |
Foley ToddDirector
|
SaleCommon Stock | 74,225 | $23.31 | $1,730,184.75 |
DisclosureSEC source: 0001209191-19-058413 · doc4.xml · nonDerivative · entry 1 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,570,355 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: Shares were sold as follows: 71,449 by BV V and 2,776 by AM BV5. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.71 to $23.56. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · ownership.nature: Shares are held as follows: 2,474,236 by BV V and 96,119 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:22 UTC |
Foley ToddDirector
|
SaleCommon Stock | 50,320 | $23.34 | $1,174,468.80 |
DisclosureSEC source: 0001209191-19-058110 · doc4.xml · nonDerivative · entry 4 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,644,580 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · shares: Shares were sold as follows: 48,438 by BV V and 1,882 by AM BV5. F11 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.29 to $23.39. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F12 · ownership.nature: Shares are held as follows: 2,545,685 by BV V and 98,895 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:22 UTC |
Foley ToddDirector
|
SaleCommon Stock | 71,023 | $23.04 | $1,636,369.92 |
DisclosureSEC source: 0001209191-19-058110 · doc4.xml · nonDerivative · entry 3 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,694,900 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · shares: Shares were sold as follows: 68,367 by BV V and 2,656 by AM BV5. F8 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.29 to $23.28. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F9 · ownership.nature: Shares are held as follows: 2,594,123 by BV V and 100,777 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 21:22 UTC |
Foley ToddDirector
|
SaleCommon Stock | 1,171 | $22.04 | $25,808.84 |
DisclosureSEC source: 0001209191-19-058110 · doc4.xml · nonDerivative · entry 2 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,765,923 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · shares: Shares were sold as follows: 1,127 by BV V and 44 by AM BV5. F6 · ownership.nature: Shares are held as follows: 2,662,490 by BV V and 103,433 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 21:22 UTC |
Foley ToddDirector
|
SaleCommon Stock | 101,511 | $21.78 | $2,210,909.58 |
DisclosureSEC source: 0001209191-19-058110 · doc4.xml · nonDerivative · entry 1 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,767,094 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: The shares were sold as follows: 97,715 by MPM BioVentures V, L.P. ("BV V") and 3,796 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $21.025 to $22.00. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · ownership.nature: Shares are held as follows: 2,663,617 by BV V and 103,477 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 22:30 UTC |
Foley ToddDirector
|
SaleCommon Stock | 5,457 | $21.09 | $115,088.13 |
DisclosureSEC source: 0001209191-19-057850 · doc4.xml · nonDerivative · entry 3 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,868,605 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · shares: Shares were sold as follows: 5,253 by BV V and 204 by AM BV5. F9 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $21.00 to $21.28. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F10 · ownership.nature: Shares are held as follows: 2,761,332 by BV V and 107,273 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 22:30 UTC |
Foley ToddDirector
|
SaleCommon Stock | 59,466 | $20.50 | $1,219,053.00 |
DisclosureSEC source: 0001209191-19-057850 · doc4.xml · nonDerivative · entry 2 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,874,062 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · shares: Shares were sold as follows: 57,242 by BV V and 2,224 by AM BV5. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.00 to $20.99. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F7 · ownership.nature: Shares are held as follows: 2,766,585 by BV V and 107,477 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 22:30 UTC |
Foley ToddDirector
|
SaleCommon Stock | 141,365 | $22.02 | $3,112,857.30 |
DisclosureSEC source: 0001209191-19-057850 · doc4.xml · nonDerivative · entry 1 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,933,528 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: The shares were sold as follows: 136,079 by MPM BioVentures V, L.P. ("BV V") and 5,286 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $21.59 to $22.58. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · ownership.nature: Shares are held as follows: 2,823,827 by BV V and 109,701 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 12, 2019 Filed Aug 13, 2019 20:04 UTC |
Desikan NithyaChief Commercial Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 14,534 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001104659-19-045574 · a4.xml · derivative · entry 2 Desikan Nithya · CIK 0001714105 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,676 Underlying: Common Stock · 14,534 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options were granted on August 9, 2017. 32,715 of the total shares vested and became exercisable immediately upon grant. 25% of the remaining stock options vested and became exercisable on July 23, 2018. 75% of the remaining stock options shall vest in 36 successive, equal monthly installments with the first such installment vesting and becoming exercisable on August 23, 2018. Read SEC document |
| August 12, 2019 Filed Aug 13, 2019 20:04 UTC |
Desikan NithyaChief Commercial Officer
|
Exercise / conversionCommon Stock | 14,534 | $6.88 | $99,993.92 |
DisclosureSEC source: 0001104659-19-045574 · a4.xml · nonDerivative · entry 1 Desikan Nithya · CIK 0001714105 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2019 Filed Aug 1, 2019 20:06 UTC |
Arbuckle Stuart ADirector
|
GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $19.05 | $0.00 |
DisclosureSEC source: 0001104659-19-043324 · a4.xml · derivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-07-29 F1 · derivative.exercise_date: One-third of the options will vest on each one-year anniversary of the grant date, with the first one-third vesting on July 30, 2020. Read SEC document |
| July 16, 2019 Filed Jul 17, 2019 20:11 UTC |
Gottesdiener Keith MichaelDirector · CEO and President
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001104659-19-040756 · a4.xml · derivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,280 Underlying: Common Stock · 7,500 shares Expires 2025-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015. Read SEC document |
| July 16, 2019 Filed Jul 17, 2019 20:11 UTC |
Gottesdiener Keith MichaelDirector · CEO and President
|
Exercise / conversionCommon Stock | 7,500 | $4.59 | $34,425.00 |
DisclosureSEC source: 0001104659-19-040756 · a4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 513,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 11, 2019 Filed Jul 15, 2019 20:01 UTC |
Smith Hunter CChief Financial Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001104659-19-040345 · a4.xml · derivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,744 Underlying: Common Stock · 10,000 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options were granted on August 9, 2017. 25% of the stock options vested and became exercisable on July 31, 2018. 75% of the stock options shall vest in 36 successive, equal monthly installments with the first such installment vesting and becoming exercisable on August 31, 2018. Read SEC document |
| July 11, 2019 Filed Jul 15, 2019 20:01 UTC |
Smith Hunter CChief Financial Officer
|
Exercise / conversionCommon Stock | 10,000 | $6.88 | $68,800.00 |
DisclosureSEC source: 0001104659-19-040345 · a4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:13 UTC |
Foley ToddDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $22.93 | $0.00 |
DisclosureSEC source: 0001104659-19-037017 · a4.xml · derivative · entry 1 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:17 UTC |
Mathers Edward TDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $22.93 | $0.00 |
DisclosureSEC source: 0001209191-19-038465 · doc4.xml · derivative · entry 1 Mathers Edward T · CIK 0001328625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:15 UTC |
GOOD JENNIFER LDirector
|
GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $22.93 | $0.00 |
DisclosureSEC source: 0001104659-19-037021 · a4.xml · derivative · entry 1 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: One-third of the options will vest on each one-year anniversary of the grant date, with the first one-third vesting on June 19, 2020. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:14 UTC |
MCGIRR DAVID W JDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $22.93 | $0.00 |
DisclosureSEC source: 0001104659-19-037019 · a4.xml · derivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:14 UTC |
Meeker David PDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $22.93 | $0.00 |
DisclosureSEC source: 0001104659-19-037018 · a4.xml · derivative · entry 1 Meeker David P · CIK 0001385155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:13 UTC |
JEAN CHRISTOPHEDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $22.93 | $0.00 |
DisclosureSEC source: 0001104659-19-037016 · a4.xml · derivative · entry 1 JEAN CHRISTOPHE · CIK 0001378435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 16:00 UTC |
Van der Ploeg Leonardus H.T.Chief Scientific Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001104659-19-033437 · a4.xml · derivative · entry 6 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,611 Underlying: Common Stock · 5,000 shares Expires 2025-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 16:00 UTC |
Van der Ploeg Leonardus H.T.Chief Scientific Officer
|
SaleCommon Stock | 5,000 | $25.10 | $125,500.00 |
DisclosureSEC source: 0001104659-19-033437 · a4.xml · nonDerivative · entry 4 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,339 F2 · price: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.33, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 16:00 UTC |
Van der Ploeg Leonardus H.T.Chief Scientific Officer
|
Exercise / conversionCommon Stock | 5,000 | $4.59 | $22,950.00 |
DisclosureSEC source: 0001104659-19-033437 · a4.xml · nonDerivative · entry 3 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 16:00 UTC |
Van der Ploeg Leonardus H.T.Chief Scientific Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001104659-19-033437 · a4.xml · derivative · entry 5 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,611 Underlying: Common Stock · 5,000 shares Expires 2025-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 16:00 UTC |
Van der Ploeg Leonardus H.T.Chief Scientific Officer
|
SaleCommon Stock | 5,000 | $25.31 | $126,550.00 |
DisclosureSEC source: 0001104659-19-033437 · a4.xml · nonDerivative · entry 2 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,339 F1 · price: This transaction was executed in multiple trades at prices ranging from $25.11 to $25.64, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 16:00 UTC |
Van der Ploeg Leonardus H.T.Chief Scientific Officer
|
Exercise / conversionCommon Stock | 5,000 | $4.59 | $22,950.00 |
DisclosureSEC source: 0001104659-19-033437 · a4.xml · nonDerivative · entry 1 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2019 Filed May 30, 2019 16:01 UTC |
Van der Ploeg Leonardus H.T.Chief Scientific Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001104659-19-032725 · a4.xml · derivative · entry 8 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,611 Underlying: Common Stock · 5,000 shares Expires 2025-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015. Read SEC document |
| May 29, 2019 Filed May 30, 2019 16:01 UTC |
Van der Ploeg Leonardus H.T.Chief Scientific Officer
|
SaleCommon Stock | 5,000 | $25.51 | $127,550.00 |
DisclosureSEC source: 0001104659-19-032725 · a4.xml · nonDerivative · entry 5 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,339 F2 · price: This transaction was executed in multiple trades at prices ranging from $25.18 to $26.02, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 29, 2019 Filed May 30, 2019 16:01 UTC |
Van der Ploeg Leonardus H.T.Chief Scientific Officer
|
Exercise / conversionCommon Stock | 5,000 | $4.59 | $22,950.00 |
DisclosureSEC source: 0001104659-19-032725 · a4.xml · nonDerivative · entry 4 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2019 Filed May 30, 2019 16:01 UTC |
Van der Ploeg Leonardus H.T.Chief Scientific Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 140 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0001104659-19-032725 · a4.xml · derivative · entry 7 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,290 Underlying: Common Stock · 140 shares Expires 2027-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from January 6, 2017. Read SEC document |
| May 28, 2019 Filed May 30, 2019 16:01 UTC |
Van der Ploeg Leonardus H.T.Chief Scientific Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 9,860 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001104659-19-032725 · a4.xml · derivative · entry 6 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,611 Underlying: Common Stock · 9,860 shares Expires 2025-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015. Read SEC document |
| May 28, 2019 Filed May 30, 2019 16:01 UTC |
Van der Ploeg Leonardus H.T.Chief Scientific Officer
|
SaleCommon Stock | 10,000 | $25.38 | $253,800.00 |
DisclosureSEC source: 0001104659-19-032725 · a4.xml · nonDerivative · entry 3 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,339 F1 · price: This transaction was executed in multiple trades at prices ranging from $25.01 to $26.10, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 28, 2019 Filed May 30, 2019 16:01 UTC |
Van der Ploeg Leonardus H.T.Chief Scientific Officer
|
Exercise / conversionCommon Stock | 140 | $6.14 | $859.60 |
DisclosureSEC source: 0001104659-19-032725 · a4.xml · nonDerivative · entry 2 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2019 Filed May 30, 2019 16:01 UTC |
Van der Ploeg Leonardus H.T.Chief Scientific Officer
|
Exercise / conversionCommon Stock | 9,860 | $4.59 | $45,257.40 |
DisclosureSEC source: 0001104659-19-032725 · a4.xml · nonDerivative · entry 1 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2019 Filed Mar 19, 2019 20:25 UTC |
Gottesdiener Keith MichaelDirector · CEO & President
|
SaleCommon Stock | 2,329 | $30.27 | $70,498.83 |
DisclosureSEC source: 0001104659-19-015985 · a4.xml · nonDerivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 506,342 F3 · kind: On March 18, 2019, Mr. Gottesdiener sold 2,329 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This transaction was executed in multiple trades at prices ranging from $30.09 to $30.50, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 20:25 UTC |
Gottesdiener Keith MichaelDirector · CEO & President
|
SaleCommon Stock | 7,961 | $30.04 | $239,148.44 |
DisclosureSEC source: 0001104659-19-015985 · a4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 508,671 F1 · kind: On March 15, 2019, Mr. Gottesdiener sold 7,961 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.20, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 20:01 UTC |
Gottesdiener Keith MichaelDirector · CEO & President
|
SaleCommon Stock | 1,506 | $30.05 | $45,255.30 |
DisclosureSEC source: 0001104659-19-015281 · a4.xml · nonDerivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 516,632 F4 · kind: On March 14, 2019, Mr. Gottesdiener sold 1,506 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.50, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:01 UTC |
Gottesdiener Keith MichaelDirector · CEO & President
|
SaleCommon Stock | 7,782 | $30.06 | $233,926.92 |
DisclosureSEC source: 0001104659-19-015281 · a4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 518,138 F1 · kind: On March 13, 2019, Mr. Gottesdiener sold 7,782 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.20, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes 303 shares acquired under the issuer's 2017 Employee Stock Purchase Plan on February 28, 2019. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 21:01 UTC |
Gottesdiener Keith MichaelDirector · CEO and President
|
SaleCommon Stock | 1,814 | $30.01 | $54,438.14 |
DisclosureSEC source: 0001104659-19-011530 · a4.xml · nonDerivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 525,617 F3 · kind: On February 27, 2019, Mr. Gottesdiener sold 1,814 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.09, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:01 UTC |
Gottesdiener Keith MichaelDirector · CEO and President
|
SaleCommon Stock | 635 | $30.13 | $19,132.55 |
DisclosureSEC source: 0001104659-19-011530 · a4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 527,431 F1 · kind: On February 26, 2019, Mr. Gottesdiener sold 635 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.01 to $30.14, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 21:01 UTC |
Gottesdiener Keith MichaelDirector · CEO and President
|
SaleCommon Stock | 918 | $30.05 | $27,585.90 |
DisclosureSEC source: 0001104659-19-009555 · a4.xml · nonDerivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 528,066 F3 · kind: On February 19, 2019, Mr. Gottesdiener sold 918 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 21:01 UTC |
Gottesdiener Keith MichaelDirector · CEO and President
|
SaleCommon Stock | 12,002 | $30.02 | $360,300.04 |
DisclosureSEC source: 0001104659-19-009555 · a4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 528,984 F1 · kind: On February 15, 2019, Mr. Gottesdiener sold 12,002 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.18, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 16:08 UTC |
Van der Ploeg Leonardus H.T.Chief Scientific Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $29.78 | $0.00 |
DisclosureSEC source: 0001104659-19-009040 · a4.xml · derivative · entry 1 Van der Ploeg Leonardus H.T. · CIK 0001615726 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-02-12 F1 · derivative.exercise_date: This option was granted on February 13, 2019 and the shares underlying this option vest in sixteen equal quarterly installments beginning on May 13, 2019. Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 21:09 UTC |
Gottesdiener Keith MichaelDirector · CEO and President
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $29.78 | $0.00 |
DisclosureSEC source: 0001104659-19-009043 · a4.xml · derivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2029-02-12 F3 · derivative.exercise_date: This option was granted on February 13, 2019 and the shares underlying this option vest in sixteen equal quarterly installments beginning on May 13, 2019. Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 21:09 UTC |
Gottesdiener Keith MichaelDirector · CEO and President
|
SaleCommon Stock | 3,934 | $30.00 | $118,020.00 |
DisclosureSEC source: 0001104659-19-009043 · a4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,986 F1 · kind: On February 13, 2019, Mr. Gottesdiener sold 3,934 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.03, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 21:10 UTC |
Smith Hunter CChief Financial Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $29.78 | $0.00 |
DisclosureSEC source: 0001104659-19-009044 · a4.xml · derivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-02-12 F1 · derivative.exercise_date: This option was granted on February 13, 2019 and the shares underlying this option vest in sixteen equal quarterly installments beginning on May 13, 2019. Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 21:09 UTC |
Desikan NithyaChief Commercial Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $29.78 | $0.00 |
DisclosureSEC source: 0001104659-19-009042 · a4.xml · derivative · entry 1 Desikan Nithya · CIK 0001714105 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-02-12 F1 · derivative.exercise_date: This option was granted on February 13, 2019 and the shares underlying this option vest in sixteen equal quarterly installments beginning on May 13, 2019. Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 21:08 UTC |
Stewart MurrayChief Medical Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $29.78 | $0.00 |
DisclosureSEC source: 0001104659-19-009041 · a4.xml · derivative · entry 1 Stewart Murray · CIK 0001723450 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-02-12 F1 · derivative.exercise_date: This option was granted on February 13, 2019 and the shares underlying this option vest in sixteen equal quarterly installments beginning on May 13, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.